Retinal Endothelial Cell-Specific Promoter for Targeted Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene expression systems for mammalian cells lack specificity and efficiency, particularly for targeting retinal endothelial cells, which are crucial for studying neurodegenerative disorders and vision-related conditions, as existing promoters do not effectively drive gene expression in these cells.
Innovation Solution
A novel nucleic acid sequence specifically drives gene expression in retinal endothelial cells by acting as a promoter, allowing for targeted expression of genes in these cells, which can be used in expression cassettes and vectors to achieve high specificity and efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Power
If common viral promoters (CMV, SV40, RSV) are used for gene expression, then strong and robust expression is achieved in several cell types, but cell-type specificity is lost and expression occurs in unwanted cell types
Solution Approach 1:
The patent applies local quality by using a promoter sequence (SEQ ID NO:1) that is specifically adapted for retinal endothelial cells. The promoter contains retinal endothelial cell-specific regulatory elements and transcription factor binding sites, enabling strong gene expression only in this specific cell type while avoiding expression in other cell types. This resolves the contradiction by customizing the promoter's regulatory properties to match the target cell type's specific transcriptional machinery.
Solution Approach 2:
The patent changes the promoter's sequence parameters by incorporating specific regulatory motifs and transcription factor binding sites characteristic of retinal endothelial cells. The promoter sequence is optimized with specific nucleotide arrangements that respond to cell-type-specific transcription factors, thereby achieving both high expression levels and cell-type specificity simultaneously.
2Adaptability or versatility
If cellular promoters from house-keeping genes are used, then cell-type specificity is improved, but expression strength and robustness are reduced compared to viral promoters
Solution Approach 1:
The patent creates a universal solution by designing a promoter sequence that combines the specificity of cellular promoters with the strength of viral promoters. The promoter (SEQ ID NO:1) integrates multiple functional elements including strong transcriptional initiation sites and specific regulatory sequences that work together to provide both high expression levels and cell-type specificity, effectively bridging the gap between cellular and viral promoter characteristics.
Solution Approach 2:
The patent uses a composite promoter structure that combines various regulatory elements, transcription factor binding sites, and core promoter sequences into a single functional unit. This composite design allows the promoter to exhibit both strong expression capability and cell-type specificity by integrating the beneficial features of different promoter types.
3Reliability
If endogenous regulatory elements are used for transgene expression, then expression occurs in the native environment with appropriate trans-acting factors, but functional characterization is insufficient and expression control is unpredictable
Solution Approach 1:
The patent applies preliminary action by performing extensive in silico analysis and characterization of the promoter sequence before use. The promoter (SEQ ID NO:1) has been pre-analyzed for transcription factor binding sites, regulatory motifs, and potential interfering elements. This preliminary characterization allows predictable expression control and reduces the need for extensive trial-and-error experimentation, thereby reducing the difficulty of detecting and measuring promoter functionality.
Data Source
AI summary
The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 600 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in retinal endothelial cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.